Goldhirsch A, Neuenschwander H, Castiglione M, Senn H J, Cavalli F
Servizio oncologico cantonale, Ospedale San Giovanni, Bellinzona/Ospedale Civico, Lugano.
Schweiz Med Wochenschr. 1990 Nov 24;120(47):1771-83.
Adjuvant systemic therapy of breast cancer has been shown to reduce relapses and prolong survival in the women treated. This is true of all subpopulations studied. Six-month multidrug chemotherapy in premenopausal patients, and tamoxifen or short-term chemotherapy in postmenopausal patients, are the treatments of choice in reducing the risk of relapse. In the near future ongoing research may answer some of the open questions surrounding the definition of populations for which the risk of relapse justifies therapy and the optimum manner of using available therapies. The modest but real improvement in prognosis of operable breast cancer was obtained solely by means of clinical trials. Participation in clinical research programs is becoming medically and socially mandatory.
乳腺癌的辅助全身治疗已被证明可减少接受治疗女性的复发并延长生存期。在所有研究的亚组中都是如此。绝经前患者进行六个月的多药化疗，绝经后患者使用他莫昔芬或短期化疗，是降低复发风险的首选治疗方法。在不久的将来，正在进行的研究可能会回答一些围绕复发风险足以证明治疗合理的人群定义以及使用现有治疗方法的最佳方式等尚未解决的问题。可手术乳腺癌预后的适度但真实的改善完全是通过临床试验获得的。参与临床研究项目在医学和社会层面正变得必不可少。
